UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.53 USD | -0.22% |
|
-3.00% | -33.09% |
| Apr. 12 | Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director | CI |
| Apr. 02 | UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating | MT |
| Sales 2024 * | 55.57M 59.42M | Sales 2025 * | 78.26M 83.68M | Capitalization | 206M 220M |
|---|---|---|---|---|---|
| Net income 2024 * | -202M -216M | Net income 2025 * | -182M -195M | EV / Sales 2024 * | 2.7 x |
| Net cash position 2024 * | 55.78M 59.64M | Net cash position 2025 * | 50.83M 54.35M | EV / Sales 2025 * | 1.98 x |
| P/E ratio 2024 * |
-1.05
x | P/E ratio 2025 * |
-1.2
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | -0.22% | ||
| 1 week | -3.00% | ||
| Current month | -12.88% | ||
| 1 month | -14.85% | ||
| 3 months | -22.30% | ||
| 6 months | -22.16% | ||
| Current year | -33.09% |
1 week
4.35
4.90
1 month
4.355.48
Current year
4.357.12
1 year
4.3522.48
3 years
4.3538.80
5 years
4.3582.49
10 years
4.3582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 14-12-31 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 14-12-31 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 20-06-16 |
Jack Kaye
BRD | Director/Board Member | 80 | 16-06-14 |
| Director/Board Member | 61 | 17-09-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 16 M€ | -8.49% | ||
| 0.48% | 29 M€ | -4.33% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.53 | -0.22% | 354,544 |
| 24-04-25 | 4.54 | -0.44% | 505,895 |
| 24-04-24 | 4.56 | -4.00% | 635,827 |
| 24-04-23 | 4.75 | -1.45% | 461,597 |
| 24-04-22 | 4.82 | +3.21% | 380,094 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
2024-04-28
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.243
EUR
Average target price
18.98
EUR
Spread / Average Target
+347.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.09% | 220M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- QURE Stock
